000			02199 a2200589 4500
005			20250517014728.0
264		0	_c20160225
008			201602s 0 0 eng d
022			_a2152-2669
024	7		_a10.1016/j.clml.2014.12.016 _2doi
040			_aNLM _beng _cNLM
100	1		_aAyala, Ernesto
245	0	0	_aMyeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. _h[electronic resource]
260			_bClinical lymphoma, myeloma & leukemia _cJun 2015
300			_a335-40 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Intravenous
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aBusulfan _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aGraft vs Host Disease _xprevention & control
650	0	4	_aHematopoietic Stem Cell Transplantation _xadverse effects
650	0	4	_aHumans
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aLymphoma, Non-Hodgkin _xmortality
650	0	4	_aMale
650	0	4	_aMethotrexate _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aMyeloablative Agonists _xadministration & dosage
650	0	4	_aRecurrence
650	0	4	_aRetrospective Studies
650	0	4	_aSurvival Rate
650	0	4	_aTacrolimus _xtherapeutic use
650	0	4	_aTransplantation Conditioning _xmethods
650	0	4	_aTransplantation, Homologous
650	0	4	_aVidarabine _xadministration & dosage
700	1		_aFigueroa, Javier
700	1		_aPerkins, Janelle
700	1		_aKim, Jongphil
700	1		_aYue, Binglin
700	1		_aRiches, Marcie
700	1		_aNishihori, Taiga
700	1		_aLocke, Frederick
700	1		_aAnasetti, Claudio
700	1		_aKharfan-Dabaja, Mohamed A
773	0		_tClinical lymphoma, myeloma & leukemia _gvol. 15 _gno. 6 _gp. 335-40
856	4	0	_uhttps://doi.org/10.1016/j.clml.2014.12.016 _zAvailable from publisher's website
999			_c24601988 _d24601988